Reviva Pharmaceuticals appoints Baker Tilly as new auditor after Moss Adams merger

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Moss Adams LLP merged with Baker Tilly US, LLP effective June 3, 2025; Moss Adams resigned as auditor the same day.
Audit Committee appointed Baker Tilly as successor independent registered public accounting firm effective June 3, 2025.
No disagreements or reportable events occurred with Moss Adams during fiscal years 2024-2025 interim period.
Prior audit reports included a going concern explanatory paragraph; no adverse or qualified opinions issued.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.